Patient-Derived Gastric Cancer Assembloids Model Tumor-Strom
2026-06-19
This study introduces a patient-derived gastric cancer assembloid model that integrates matched tumor organoids with autologous stromal cell subpopulations. By closely recapitulating the cellular heterogeneity and microenvironment of primary tumors, the model enables more physiologically relevant analyses of gene expression, drug responsiveness, and resistance mechanisms, offering a robust platform for personalized therapy research.
Digestive Transformations of Ashwagandha: LC–MS/MS Insights
2026-06-19
This study pioneers a comprehensive LC–MS/MS and molecular networking approach to map the digestive fate of key withanolides in Withania somnifera extracts. By revealing differential stability among bioactive compounds during simulated digestion, the findings inform improved in vitro pharmacokinetic models for botanical medicines.
Technical Use of Angiotensin I/II (1-5) in RAS Research Work
2026-06-18
Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide fragment to support mechanistic studies in blood pressure regulation and aldosterone signaling within the renin-angiotensin system. It is not suitable for workflows outside cardiovascular or renal research due to its biochemical specificity and solubility constraints. For optimal results, researchers should adhere to established storage and preparation protocols.
TAK-715: Potent p38 MAPK Inhibitor for Inflammation Research
2026-06-18
TAK-715 is a highly selective p38 MAPK inhibitor that targets the p38α isoform with nanomolar potency. It enables precise modulation of cytokine signaling and inflammation in both in vitro and in vivo models, supporting advanced research into chronic inflammatory diseases.
5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole: Protocols & I
2026-06-17
5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) is a benchmark transcriptional elongation inhibitor offering precise inhibition of cyclin-dependent kinases, pivotal for dissecting RNA polymerase II function, antiviral response, and cell fate transitions. This guide translates recent breakthroughs—such as spatial RNA interaction mapping and ac4C-modified lncRNA studies—into actionable workflows and troubleshooting strategies for maximizing DRB’s utility in advanced molecular biology research.
Crizotinib Hydrochloride: ALK Kinase Inhibitor in Tumor Asse
2026-06-17
Crizotinib hydrochloride enables precise interrogation of ALK and ROS1-driven oncogenic pathways in physiologically relevant assembloid models. Leveraging APExBIO’s high-purity inhibitor, researchers can dissect tumor–stroma interactions and optimize drug response profiling for next-generation cancer biology research.
Bestatin as a Chemical Genetics Tool in Jasmonate Signaling
2026-06-16
The reference study establishes bestatin as a precise chemical genetics tool for dissecting jasmonate (JA) signaling pathways in Arabidopsis. By leveraging bestatin’s unique action on aminopeptidases, the researchers identify novel loci critical to JA-mediated plant defense and development, providing a robust framework for future signaling and cytoskeletal studies.
Capsaicin: Advanced TRPV1 Modulation and Epigenetic Research
2026-06-16
Explore the unique dual mechanism of Capsaicin—TRPV1 activation and KDM1A inhibition—and uncover advanced applications in translational pain and cancer research. This deep-dive offers new protocol insights and practical assay guidance, differentiating itself from prior reviews.
Bivalent mRNA Vaccine RQ3025: Broad SARS-CoV-2 Variant Immun
2026-06-15
Lu et al. introduce RQ3025, a bivalent mRNA vaccine designed to protect against multiple SARS-CoV-2 variants by incorporating spike protein mutations from divergent viral lineages. Their preclinical work demonstrates enhanced neutralizing antibody responses and Th1-biased cellular immunity across animal models, highlighting RQ3025’s potential as a next-generation COVID-19 vaccine with broad-spectrum efficacy.
Oltipraz: Applied Protocols for Nrf2-Driven Chemoprevention
2026-06-15
Oltipraz, a potent Nrf2 pathway activator, is transforming chemopreventive and liver disease research with robust phase II enzyme induction. This guide translates recent breakthroughs—like autophagy-ferroptosis modulation in MASLD—into actionable, troubleshooting-ready workflows.
SAF312 (Libvatrep): Advancing Ocular TRPV1 Antagonism for Pa
2026-06-14
This article reviews the preclinical pharmacology and toxicology of SAF312 (Libvatrep), a selective TRPV1 antagonist evaluated for ocular surface pain. The study demonstrates SAF312’s potency, selectivity, and safety profile in relevant in vitro and in vivo models, revealing translational potential for targeted ocular analgesia without impairing corneal healing.
Toremifene Citrate in Breast Cancer Research Workflows
2026-06-13
Harnessing Toremifene Citrate as an oral selective estrogen receptor modulator (SERM) unlocks precision in breast cancer and hormone receptor signaling research. This guide translates benchmark findings and hands-on workflow optimizations into actionable protocols, troubleshooting advice, and future-focused experimental design.
BIBR 1532: Telomerase Inhibitor Workflows for Cancer Researc
2026-06-12
BIBR 1532, a selective telomerase inhibitor from APExBIO, empowers researchers to dissect telomere biology and drive apoptosis in cancer models using robust, reproducible workflows. Leverage protocol-centric insights and troubleshooting strategies to enhance telomerase activity assays and cancer cell proliferation inhibition platforms.
Syringin in Bioactive Compound Research: Mechanisms, Assay O
2026-06-12
Explore Syringin, a high-purity natural product, through the lens of advanced mechanism studies and protocol optimization. This article offers unique insights into assay design and translational relevance, setting Syringin apart in natural product research.
Rotigotine Modulates Bladder Function in Parkinson’s Disease
2026-06-11
This study elucidates how the dopamine D1/D2 receptor agonist rotigotine influences lower urinary tract function in a 6-OHDA-induced rat model of Parkinson’s disease. The findings demonstrate route- and dose-dependent effects on micturition parameters, highlighting implications for both motor and non-motor symptom management in PD research.
466 records 15/32 page Previous Next First page 上5页 1112131415 下5页 Last page